Tetrandrine tablets for connective tissue disease-related lung disease
Part of Lungs & breathing, Skin clinical trials.
This study tests if tetrandrine tablets can help people with lung disease caused by connective tissue disorders. It is for adults 18-80 who have stable treatment and meet specific health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You have lung fibrosis related to a connective tissue disease (like scleroderma or lupus).
- Your lung function test (FVC) must be at least 40% of normal.
- You must not have taken tetrandrine or similar anti-scarring drugs in the past month.
- You must not have active tuberculosis, severe liver or kidney problems, or high blood sugar.
- If you are able to have children, you must use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called NCR101 for people with interstitial lung disease (a lung condition that causes scarring). It aims to see if the drug is safe and helps slow the disease. You may be able to join if your current treatments are stable.
This trial tests a single inhaled dose of RJ026 in patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF) or connective tissue disease-related ILD (CTD-ILD). It helps see how the drug moves through the body and if it's safe.
This study tests if inhaling L-menthol can help reduce breathlessness in people with interstitial lung disease. You will cycle while breathing menthol or a placebo to see if it makes breathing easier.
This trial tests a new injection called telitacicept for people with lung scarring caused by autoimmune diseases like rheumatoid arthritis or lupus. It aims to see if the drug can slow down lung damage and help you breathe better.
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
This trial tests whether adding dextromethorphan (a common cough medicine) to nintedanib (a lung-fibrosis drug) helps slow lung damage in people with idiopathic pulmonary fibrosis (IPF)—a condition where lung tissue becomes scarred and stiff. The study lasts 12 weeks plus one follow-up visit.
Hear when a new Interstitial Lung Disease (ILD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.